clinical trial · NCT04681131
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
Non-Small-Cell Lung CancerCAB-AXL-ADCPD-1 inhibitor
brief summary
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC
started
Mar 17, 2021
primary completion
Jul 9, 2025
completion
Jul 9, 2025
last updated
Sep 25, 2025
detailed description
This is a multi-center, open-label, Phase 2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC), alone and in combination with PD-1 inhibitor in patients with metastatic non-small cell lung cancer (NSCLC).
official title
A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor, EGFR, or ALK Inhibitor.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol